Clinical Medicine Insights-Oncology

Scope & Guideline

Bridging gaps in cancer treatment and management.

Introduction

Delve into the academic richness of Clinical Medicine Insights-Oncology with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN-
PublisherSAGE PUBLICATIONS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationCLIN MED INSIGHTS-ON / Clin. Med. Insights-Oncol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

Clinical Medicine Insights-Oncology focuses on advancing the understanding, diagnosis, and treatment of various cancers through innovative research and clinical studies. The journal aims to provide a platform for disseminating findings that enhance patient outcomes and inform clinical practice.
  1. Cancer Biomarkers and Prognosis:
    The journal extensively explores the identification and validation of biomarkers that can predict cancer progression, treatment response, and patient prognosis across various cancer types.
  2. Innovative Therapeutic Strategies:
    There is a strong emphasis on novel therapeutic approaches, including immunotherapy, targeted therapies, and combination treatments that aim to improve survival rates and quality of life for cancer patients.
  3. Clinical Trials and Observational Studies:
    The journal includes findings from both clinical trials and observational studies, highlighting real-world evidence that can inform treatment protocols and clinical guidelines.
  4. Molecular and Genetic Insights:
    Research on the molecular and genetic underpinnings of cancer, including the role of specific genes and mutations in tumor behavior, is a core focus area.
  5. Patient-Centered Research:
    The journal emphasizes studies that incorporate patient perspectives and quality of life assessments, aiming to align treatment strategies with patient needs and preferences.
Recent publications in Clinical Medicine Insights-Oncology reflect a dynamic shift towards newer and more relevant themes in cancer research. The following emerging scopes highlight the growing areas of interest that are shaping the future of oncology.
  1. Immunotherapy and Checkpoint Inhibitors:
    There is a marked increase in research focused on immunotherapy, particularly checkpoint inhibitors, as they represent a significant advancement in cancer treatment, showing promise in multiple malignancies.
  2. Liquid Biopsies and Non-Invasive Diagnostics:
    Emerging studies are increasingly investigating the utility of liquid biopsies for early cancer detection and monitoring treatment response, highlighting a trend towards less invasive diagnostic methods.
  3. Artificial Intelligence in Oncology:
    The application of artificial intelligence and machine learning in cancer diagnostics, treatment planning, and outcome prediction is gaining traction, indicating a technological shift in oncology research.
  4. Personalized Medicine and Genomic Profiling:
    A growing emphasis on personalized medicine, particularly through genomic profiling, is evident, as researchers seek to tailor treatments based on individual tumor characteristics.
  5. Patient-Reported Outcomes and Quality of Life:
    Research focusing on patient-reported outcomes and quality of life assessments is increasingly prevalent, reflecting a holistic approach to cancer treatment that values patient perspectives.

Declining or Waning

While Clinical Medicine Insights-Oncology continues to explore a broad range of cancer-related topics, certain themes have shown a decline in frequency and focus over recent years. The following areas may be experiencing waning interest or relevance in the current landscape of oncology research.
  1. Traditional Chemotherapy Approaches:
    There appears to be a declining focus on traditional chemotherapy regimens, as newer therapies such as immunotherapy and targeted treatments gain prominence in clinical practice and research.
  2. Basic Science Without Clinical Application:
    Research that does not translate into clinical applications or that lacks direct implications for patient care seems to be less frequent, as the journal increasingly prioritizes studies with clear clinical relevance.
  3. General Cancer Epidemiology Studies:
    While still important, studies solely focused on cancer epidemiology without specific interventions or treatment implications may be receiving less attention compared to research that directly influences treatment decisions.

Similar Journals

Oncology in Clinical Practice

Bridging Clinical Insights and Cancer Research
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

Journal of Thoracic Oncology

Leading the Charge in Thoracic Malignancy Insights
Publisher: ELSEVIER SCIENCE INCISSN: 1556-0864Frequency: 12 issues/year

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Cancer Management and Research

Connecting researchers to redefine cancer care.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Nature Reviews Clinical Oncology

Connecting Knowledge and Innovation in Oncology
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Future Oncology

Bridging laboratory innovation with clinical excellence.
Publisher: FUTURE MEDICINE LTDISSN: 1479-6694Frequency: 40 issues/year

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Pioneering insights in gynecological cancer treatment.
Publisher: BMJ PUBLISHING GROUPISSN: 1048-891XFrequency: 9 issues/year

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, published by BMJ PUBLISHING GROUP, is a leading interdisciplinary journal focused on advancing research and clinical practice in the field of gynecological oncology. With an ISSN of 1048-891X and an E-ISSN of 1525-1438, the journal has established itself as a vital resource since its inception in 1991, covering cutting-edge advancements through 2024 and beyond. The journal holds esteemed rankings, including Q1 in Obstetrics and Gynecology and Q2 in Oncology, highlighting its influence and high citation impact within the medical community. Its Scopus rankings underscore its prominence, placing it among the top 13% of journals in Obstetrics and Gynecology and the top 27% in Oncology. Although it does not currently offer Open Access options, the journal provides a platform for researchers, clinicians, and students to share significant findings and developments that shape the future of gynecological cancer research and treatment. The INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER stands as a significant pillar in the ongoing effort to improve patient outcomes and foster innovation in this critical area of healthcare.

BRITISH JOURNAL OF CANCER

Elevating the Standards of Cancer Research.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

International Journal of Breast Cancer

Unlocking breakthroughs in breast cancer science.
Publisher: HINDAWI LTDISSN: 2090-3170Frequency:

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.

Tumori Journal

Elevating Oncology Knowledge for a Healthier Tomorrow.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Journal of Cancer

Pioneering discoveries in the realm of oncology.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.